Biotech "Tweets of the Week"
3rd Quarter Ends with Busy News Week
(September 26-30, 2016)
Headlines - $AUPH $DEPO $GILD $ITCI $KITE $PBYI $SRPT
In the News - $ABUS $ADHD $ALNY $ARRY $CELG $GALT $GLPG $GWPH $MRNS $PTIE $SMMT $XBI $IBB
Looking for past biotech highlights? Check out the Biotech Tweets of the Week archive.
Sarepta's eteplirsen story pivots to commercialization $SRPT
ICYMI: great @BioCentury piece on Exondys' $300k price, including potential payer reactions, limits on access, etc. https://t.co/JKWuuxhboE
— Rachel Sachs (@RESachs) September 27, 2016
Most docs expect to prescribe Sarepta drug for Duchenne despite insurance concerns. see survey results https://t.co/TrQcykuhDV #pharma $SRPT
— pharmalot (@pharmalot) September 27, 2016
Richard Mosicki, FDA’a Deputy Center Director for Science Ops, says eteplirsen approval was "science-based decision.” $SRPT #STATHUBweek
— Adam Feuerstein (@adamfeuerstein) September 27, 2016
$SRPT JMP believes $300K net price too low as avg weight much higher than 25kg, projects avg gross price of $538K, or a net price of $457K.
— Andy Biotech (@AndyBiotech) September 28, 2016
*SAREPTA'S MUSCULAR DYSTROPHY DRUG GET BROAD COVERAGE FROM CIGNA $SRPT
— zach (@zbiotech) September 28, 2016
$SRPT Announces First Patient Dosed in Phase III Clinical Trial of SRP-4045 and SR-4053... https://t.co/hFfgukPOlw
— Joe (@GantosJ) September 28, 2016
$SRPT just saw a post from a friend about her son. Their insurance has approved #Exondys51 his first dose is on its way! #whywedowhatwedo
— jenn mcnary (@jennmcnary) September 28, 2016
$SRPT
— Tom Wrigley (@WrigleyTom) September 29, 2016
Catabasis Pharmaceuticals And Sarepta Therapeutics Announce A Joint Research Collaboration In Duchenne Muscular Dystrophy -Dow Jones
"Start Here" - click on this tweet for the conversation that ensued
Here's the problem with no pay-for-performance for Exondys: There is literally no upside for $SRPT to confirm benefit, but $billions at risk
— Michelle Fay Cortez (@FayCortez) September 28, 2016
"Did Kite just win CAR-T or do you want to see more data?" $KITE $JUNO
$KITE says KTE-C19 hits primary endpoint in interim read of ZUMA-1, two patients died --- via @business
— Caroline Chen (@CarolineYLChen) September 26, 2016
@bradloncar Yes. Talking to FDA in the next month and will be more specific about timing after those discussions. $KITE
— Mandy Jackson (@ScripMandy) September 26, 2016
$KITE neurotox in 34% - wonder how much of that is cerebral edema? cy/flu preconditioning will certainly be scrutinized by FDA
— Red Acre Investments (@redacre) September 26, 2016
Hmmm $KITE meh it's not no. of CRs, it's how durable they are. Too many relapsing by 3 months. Come final data set that could be worse
— Sally Church (@MaverickNY) September 26, 2016
$KITE — Good thing all the sell-side analysts walked back ZUMA-1 CR expectations. I suspect they’ll be doing more of that tonight.
— Adam Feuerstein (@adamfeuerstein) September 26, 2016
Discussing the $KITE data with the smartest mind at #CICON16, @PDRennert. pic.twitter.com/QZPjff2Tib
— Brad Loncar (@bradloncar) September 26, 2016
Did $KITE just win CAR-T or do you want to see more data? My take on Zuma-1 via @EPVantage https://t.co/ldFSbId8O6 $JUNO $NVS #ASH16
— Jacob Plieth (@JacobPlieth) September 27, 2016
$KITE product profile:
— Biotech, Beats & BBQ (@BiotechBbqBeats) September 27, 2016
Kills you ~4% of the time
Major tox >66% of the time
Does its job <33% of the time
COGS $250K (or more)
...Priceless?
Analyst note pans Gilead management and strategy $GILD
Leerink’s Porges abandons $GILD, downgrades to market perform, cuts PT to $94 from $112. Cites deteriorating HepC biz, nothing to replace.
— Adam Feuerstein (@adamfeuerstein) September 27, 2016
Porges note on $gild is brutal. Fears company has been paralyzed by its size and good fortune.
— Matthew Herper (@matthewherper) September 27, 2016
6 months ago $GILD could have bought $ICPT $GLPG $GBT $KITE $TSRO for under $15 billion after paying a 50% premium
— Dan Rosenblum (@sharkbiotech) September 27, 2016
@adamfeuerstein On the morning that Kyprolis failed in 1L, we're talking about what morons $GILD is for not doing more big deals.
— Brad Loncar (@bradloncar) September 27, 2016
Need to consider the possibility of $GILD becoming a target itself for Big Pharma, if only for its massive cash pile. Still makes BILLIONS.
— CR (@CashRocket) September 27, 2016
Can Wall Street stop ganging up on $GILD just because it refuses to throw around lavish investment banking fees?
— Dirk Haussecker (@RNAiAnalyst) September 27, 2016
Inter-Cellular Therapies plunges on schizophrenia trial dud $ITCI
— Raj R (@rajramaswamy) September 28, 2016
Once again great call ahead of data by @AF_biotech on $ITCI, said it was way too close to call. Props
— Biotech Supernova (@biotechnova) September 28, 2016
$ITCI PR really hams up safety/tolerability rivaling placebo. Awfully tone deaf...
— Jake King (@FajaJake) September 28, 2016
$ITCI Neither dose of ITI-007 separated from placebo on the primary endpoint, risperidone did separate from placebo https://t.co/pDlDgKR9VZ
— JQ (@jq1234t) September 28, 2016
$ITCI pretty weak to blame high placebo response when the active control risperidone did separate from placebo.https://t.co/8vgp4uCkdU
— Andy Biotech (@AndyBiotech) September 28, 2016
$ITCI another bomb after $NVAX. Do not chase clinical trial data! NOT worth the risk.
— Nick zheng (@pick1998_2) September 28, 2016
$ITCI is yet another example of why US generalist investors shouldn’t be doing biotech
— David Grainger (@sciencescanner) September 28, 2016
@EdenRahim @bradloncar @biggercapital essential! Glad I picked up $20P to protect and make out positive
— Amit Jolly (@amitkjolly) September 28, 2016
So '007 is finished. '214 P1/2 data from other studies not til 2017. PDE candidates still pre-clinical. So....no rush to BTFD IMHO. $ITCI
— CR (@CashRocket) September 28, 2016
$ITCI down 67,8% in Extended hours
— Bursatil Biotech (@BursatilBiotech) September 29, 2016
$ITCI avg tgts gone from $65 to $35
— zach (@zbiotech) September 29, 2016
As seen on the stream
Nice job of a conference saying "Here's our hashtag, please comment and share what you hear and see today." #CICON16 pic.twitter.com/wgVasjvHB4
— Brad Loncar (@bradloncar) September 25, 2016
$GILD $GLPG filgotinib endoscopy data https://t.co/FRds7ILrHK double rate of 50% improvement vs placebo but not stat sig
— Andrew G. (@BioDueDiligence) September 26, 2016
Thanks to @statnews, a view of our quest to cure my currently incurable MSS-CRC with #Neoantigen approach. #cancer https://t.co/8SjPyWk3sR
— Tom Marsilje (@CurrentIncurSci) September 26, 2016
$PFE not planning on splitting up
— j l (@bio_clouseau) September 26, 2016
$GWPH up 16% pre-market on second positive phase 3 trial in Lennox-Gastaut Syndrome https://t.co/HBiCcn7CUK
— Meg Tirrell (@megtirrell) September 26, 2016
$ARRY OLUMBUS Phase 3 Study of Encorafenib plus Binimetinib For BRAF-Mutant Melanoma Met Primary Endpoint
— Bio Stocks™ (@BioStocks) September 26, 2016
$PTIE $DRRX CRL for REMOXY https://t.co/HYnMgF1WrR
— Bio Stocks™ (@BioStocks) September 26, 2016
$PTIE 'CRL focuses on the abuse-deterrent properties of remoxy' AND labeling
— zach (@zbiotech) September 26, 2016
in other words, everything that would 'differentiate' remoxy
so, a year for studies/data, file response to CRL...expect another FDA decision on remoxy sometime in in late '18
— zach (@zbiotech) September 26, 2016
Mylan's pretax EpiPen profits 60 percent higher than congressional testimony. Via @SarahKarlin: https://t.co/I09HvkID8z | Photo: AP pic.twitter.com/i0eeLTw8ik
— POLITICO Pro (@POLITICOPro) September 26, 2016
$ARRY quietly up 75% all day
— Jake King (@FajaJake) September 26, 2016
$XBI strong close (compared to $SPY). Impressive resistance to the debate/end-of-world fear mongering. If we survive tonight I'm buying more
— Oncology Now (@onconow) September 26, 2016
#FDA slaps clinical hold on $CVM Multikine Ph III head/neck cancer study; 926 patients enrolledhttps://t.co/tcuiK4qwwF #pharma #biotech
— Donna Young (@DonnaYoungDC) September 27, 2016
$SMMT receives Rare Pediatric Disease Designation for Ezutromid in Treatment of Duchenne Muscular Dystrophy
— Bio Stocks™ (@BioStocks) September 27, 2016
$BMY and $NKTR will do combos of Opdivo and NKTR-214 (CD122). https://t.co/ghy9JMb8CA
— Brad Loncar (@bradloncar) September 27, 2016
@BioStocks $MSTX will make a $10MM payment on its Hercules loan in early Oct., further weakening its already tenuous cash position.
— dough (@tgtxdough) September 27, 2016
All the alliances that @MDAndersonNews currently has on #cancer therapeutics including #immunotherapy in one placehttps://t.co/Asly5Q6RRb
— Anirban Maitra (@Aiims1742) September 27, 2016
Orbimed continues unloading $AFMD . Now down to 10% https://t.co/gougLa47tD Was 20% middle of 2015 https://t.co/UlKtxnsqqp
— j l (@bio_clouseau) September 27, 2016
$CASC meeting w/FDA 'soon' to discuss merits, endpt, etc of pII HER2CLIMB, including amendment into pivotal...expect mkt update by YE'16
— zach (@zbiotech) September 27, 2016
$CASC has doubled form the June low
— Dan Rosenblum (@sharkbiotech) September 27, 2016
yes I suck
I just want to say a big thank you to both the ding heads for not talking about drug pricing last night $IBB $SPY $XBI $XLV #Debates2016
— Brett (@BsiflingTrades) September 27, 2016
Really liked what I saw during $BLCM presentation at Ladenburg healthcare conference today. One to watch for sure.
— Bobby Shea (@robertcshea) September 27, 2016
$MRNS company has typically released PR's on Wednesday's/Thursday's. We are within a 24-48 hr window. Place your bets accordingly #data
— BioBull (@BioBull1) September 27, 2016
@srqstockpicker nice work today covering $TRIL $STML $TGTX Much appreciated -big thanks
— dough (@tgtxdough) September 27, 2016
@sharkbiotech yah bunch of good ones have doubled. I caught $AQXP & $SCYX. Think $CLDX or $ESPR could be next although I might be crazy.
— Adam Singer (@AdamSinger) September 27, 2016
$tril ash16 abstract is a go. Comfirmed today
— Boaty McBoatface (@srqstockpicker) September 27, 2016
Table of Recent Biotech Buyouts & Premiums (updated4 $BSX- $GI):https://t.co/GdiMxh0DgK
— Roy Friedman (@DewDiligence) September 27, 2016
$FOLD Crowley: Last thing I’d do is go to my board, use $SRPT as ex. of how to get drug approved. It was 1-off FDA exception. #STATHUBweek
— Adam Feuerstein (@adamfeuerstein) September 27, 2016
Novich @FujifilmUS on talent: They have retrained some people from making film to making biologics #WIBiohealth16
— Laura Strong (@scientre) September 27, 2016
$GALT designs a tiny ph2a study in NASH w/ bullshit endpoints so it can more easily declare victory… but the study still fails. Oy!
— Adam Feuerstein (@adamfeuerstein) September 27, 2016
Re-entry triggered in $DVAX from prev. LT sell after PH3 data; Intend to hold thru PDUFA,but remaining flexible while tracking to 15 Dec.
— Jason (@JasonHolman5) September 27, 2016
$CFRX I called this buy alert out at $2.45 noting the unusually high volume. Now we know why. Thanks William Blair & Co.
— The Flash (@Flashtrading) September 27, 2016
Biotech Movers 9/27:$ATNM $CCXI $CLDX $CVM $DRRX $GALT $JUNO $PTIE
— BioPharmCatalyst (@crusadernz) September 27, 2016
BPC Pipeline updates: $SAGE $TXMD $ZGNXhttps://t.co/Ky6XHeTrB7
Biotwitter is wonderful. A link to a good analytical blog post, no real comment. A quick tweet about FDA, comments everywhere. C'est la vie.
— Bruce Booth (@LifeSciVC) September 28, 2016
Recap: $arry ~18M sh @ $6.25; $myok ~4M @ $15; $fomx $irt $vsar offerings w/ unannounced prices as of yet.
— Joe (@Drchik23) September 28, 2016
$ATHX and FDA formally agree on the pIII endpoint which will define absolute failure in ischemic stroke
— zach (@zbiotech) September 28, 2016
@Drchik23 bc they will sell the co and new co will raise it immediately. That's what always happens. Only My guess tho
— Anthony (@Lblegend33) September 28, 2016
$CRBP and $NVLS continue to be on my radar. Can't predict outcome of trial, but preclinical and early clinical data favorable R/R.
— Michael Torres, PhD (@Mykalt45) September 28, 2016
the House signed off on the rare pediatric PRV extension to Dec. 31 yesterday: https://t.co/RtjVuwNypr
— Zach Brennan (@ZacharyBrennan) September 28, 2016
Julian Robertson: -Fear of Ms. Clinton has created bargains in #biotech , cites $celg as very reasonably pricedhttps://t.co/gVRFLuzavc
— Douglas Allan (@Dougallan1) September 28, 2016
This is huge -- the Americas have become the first region in the world to be declared measles-free! https://t.co/J47Bl2OkqS #VaccinesWork
— Sue Desmond-Hellmann (@SueDHellmann) September 28, 2016
$XBI We'll see if it can crack thru 69.21 and make another go at 12/30/2015 high pic.twitter.com/VFAbvO9i8g
— BioBounce.com (@BioBounce) September 28, 2016
@JSTBiotech $GBIM trades at a nano market cap and if $GILD moves forward with 4774, $GBIM is owed a large milestone payment
— Joel Thomson (@JSTBiotech) September 28, 2016
$EXEL profit taking at #ESMO16 release
— Gene Edit (@Liquid_Biopsy_) September 28, 2016
4 to 15 within 5 months
"Consider what it would be like to go into the office with fecal incontinence" $PBYI h/t @BuyersStrike https://t.co/KULzRBlCsw
— Sasha Damouni Ellis (@SashaDamouni) September 28, 2016
Uhh want to hold $ESPR into results but pre-data runups never end well
— Julia Skripka-Serry (@JuliaSkripkaSer) September 28, 2016
@zbiotech @tgtxdough Since $agn hasn't bought anyone in a week, that's certainly plausible.
— Joe (@Drchik23) September 28, 2016
I have no problem cutting losers biggest problem has always been not being able 2 stick with winners when they begin 2 go lower #IHateThat
— Executive Buying (@ExecutiveBuying) September 28, 2016
$ACAD ADP P2 data could be next CNS binary event 4Q16
— j l (@bio_clouseau) September 28, 2016
$ALNY dropping ALN-AAT due to liver enzyme elevations, back to drawing board to try and develop follow on molecule https://t.co/oW8VwPYcgv
— Vk (@biotechinvstr) September 28, 2016
Big news. FDA approves Medtronic's artificial pancreas for diabetes https://t.co/6dLAyjwSIe
— Christina Farr (@chrissyfarr) September 28, 2016
$ADHD - FDA places full clinical hold on MDX, its experimental drug for ADHD and Fragile X Syndrome. Reason: Preclinical neuro-tox.
— Adam Feuerstein (@adamfeuerstein) September 29, 2016
It took 233 days.
— Dan Diamond (@ddiamond) September 29, 2016
There are now 23,135 cases — at least.
But Congress finally passed $1.1B in Zika funding.https://t.co/ThZRHR1O4a
$BLUE and Medigene $MDG1 (covered by @EdisonHealth) in TCR deal. $15m upfront + up to $1bn in biobucks
— Juan P. Serrate, DVM (@JPZaragoza1) September 29, 2016
An Immigrant-Funded Biotech Center in Rural Vermont? What Could Go Wrong https://t.co/PFmKXyZHTq
— Arsalan Arif (@AKAarsalan) September 29, 2016
$ARWR game-plan today is to buy back the put options I've written, then sell again after the fade.
— Dirk Haussecker (@RNAiAnalyst) September 29, 2016
$MRNS data terrible. Those who got out in premarket lucky
— BNT (@CatalystWatcher) September 29, 2016
$MRNS could have written a glowing PR around responders in this tiny study. Instead they went with the science. Smarts or idiocy?
— Jake King (@FajaJake) September 29, 2016
HHS chief: EpiPen cost surge shows need for negotiating power https://t.co/zG2PcBQXKO
— Andy Slavitt (@ASlavitt) September 29, 2016
@bradloncar A biotech segment I root for every day... from the sidelines. AD, HNC, CNS disorders. Incredibly tough challenges.
— David Miller (@AlpineBV_Miller) September 29, 2016
Drug Company Manager Charged in Kickback Scheme Related to Fentanyl Spray Prescriptions $INSY https://t.co/2B4czgXU5T
— Matthew Herper (@matthewherper) September 29, 2016
Biotech is selling off quite hard today. The Biotech ETF $XBI is down over -3%, atm. $IBB is cutting under its 50-day SMA. (No pos.) pic.twitter.com/NS9rzCwEL2
— Jack Damn (@JackDamn) September 29, 2016
. @SIRF_Report For fuck’s sake, we’re dealing w/ a raging opioid crisis in this country and $INSY is bribing docs to Rx FENTANYL! Unreal.
— Adam Feuerstein (@adamfeuerstein) September 29, 2016
@codytrades yes please
— DCam (@dcamtrades) September 29, 2016
— 4th Quarter Capital (@4thQuarterCap) September 29, 2016
Adding $PRQR significantly here. Oral presentation in 4 weeks lends itself to likely positive signals in the open label CF POC trial.
— Joel Thomson (@JSTBiotech) September 29, 2016
$PBYI Employee Charged With Insider Trading Ahead of Announcements of neratinib trial datahttps://t.co/vsGnO3eM5nhttps://t.co/pIE5UA3g5w
— Andy Biotech (@AndyBiotech) September 29, 2016
$ABUS Arbutus Reports Interim Multi-Dose Results from Phase II Clinical Trial of ARB-1467 in with HBV Infection https://t.co/qU65nz7rs1
— (((BiotechSage))) (@BiotechSage) September 29, 2016
Briefing Summary: FDA Posts Advisory Committee Materials for Meeting About #Naloxone Dosing $ADAP $AMPH $INSY Kaleo https://t.co/W5W16u1qDE
— SAC Tracker (@FDAadcomm) September 29, 2016
$imgn cutting workforce 17%.
— Joe (@Drchik23) September 29, 2016
A proposition on the ballot in California has some pharmaceutical companies nervous https://t.co/b5rDGHpqdX via @markets
— Sasha Damouni Ellis (@SashaDamouni) September 29, 2016
$XBI $IBB very ugly biotech sector close. Last time with these two red back to back candle was end of August.
— PrecisionTrade365 (@BiotechMoney18) September 29, 2016
$AUPH Announces That Voclosporin Achieves Primary and All Pre-Specified Secondary Endpoints https://t.co/xh7Pm7G0Lb
— Odi (@odibro) September 29, 2016
Full $auph Voclosporin safety data to be released tmw at 8am along with webcast.
— SharpMango (@SharpMango) September 29, 2016
12 death ins the treatment arms vs. 1 in control. No matter how you spin it, it is just bad. $AUPH.
— BioResearch (@BioResearchFund) September 29, 2016
Really enjoyed writing this piece:
— John Carroll (@JohnCendpts) September 30, 2016
UCSF scientist rolls out a new blueprint for programming T cells, the 2.0 wayhttps://t.co/rXxNikvNFq
@AndyBiotech interesting. $opth being combined with Lucentis or avastin, I think. Probably a lower bar
— David Sobek (@dsobek) September 30, 2016
FDA informed $PBYI neratinib NDA was accepted under "standard review" timeline, meaning 12 months - via @TheStreet https://t.co/gLJ3nc7ZdW
— Daniel Ward (@danwardbio) September 30, 2016
Rep. Buddy Carter (R-GA) " It’s time for PBMs to step out from behind the curtain." $ESRX $CVS $UNH https://t.co/vqbR8c1YJ3
— Charley Grant (@CGrantWSJ) September 30, 2016
For the week ended September 28th, biotech had new inflows of $816M. Broke a streak of 5 weeks of outflows. (Raymond James)
— Brad Loncar (@bradloncar) September 30, 2016
$AUPH - restarted LT position in low 3's just now. 5% port.
— Raj R (@rajramaswamy) September 30, 2016
$CELG up 2%https://t.co/eNEHEslI5p
— John Carroll (@JohnCendpts) September 30, 2016
*ALLERGAN CAN'T SELL GENERIC NUCYNTA PENDING FINAL JUDGMENT $DEPO $AGN
— zach (@zbiotech) September 30, 2016
time for $AGN to make it rain for $DEPO
Its #worldheartday today. Spend a moment celebrating what has been achieved as well as campaigning for better pic.twitter.com/Tt3z3eWVnS
— David Grainger (@sciencescanner) September 29, 2016